Omadacycline (PTK 0796) hydrochloride, a first-in-class orally active aminomethylcycline antibacterial , is a member of the tetracycline class of antibiotics . Omadacycline hydrochloride acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline hydrochloride possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline hydrochloride can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections In Vitro Omadacycline displays activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumonia (PRSP) and Haemophilus influenzae (H. influenzae) , with MIC 90 s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively. Omadacycline is active against strains expressing tetracycline and other antibiotics resistance by ribosomal protection and active tetracycline efflux. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Omadacycline (0.11-18 mg/kg; a single i.v.) exhibits efficacy against Streptococcus pneumonia , Escherichia coli , and Staphylococcus aureus in mice systemic infection model, with ED 50 s ranging from 0.30 mg/kg to 3.39 mg/kg. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Tetracycline